Standard

Changing HER2-status of the primary gastric tumor after neoadjuvant trastuzumab-based therapy. / Orlova, Rashida ; Beliak, Natalia P. ; Kutukova, Svetlana ; Zhukova, Natalia V. ; Avramenko, Inna V.; Popova, Natalia V. ; Ivanova, Anastasia ; Androsova, Alexandra ; Zorina, Ekaterina .

In: Journal of Clinical Oncology, Vol. 38, No. 15 suppl, e16529, 2020.

Research output: Contribution to journalMeeting Abstractpeer-review

Harvard

Orlova, R, Beliak, NP, Kutukova, S, Zhukova, NV, Avramenko, IV, Popova, NV, Ivanova, A, Androsova, A & Zorina, E 2020, 'Changing HER2-status of the primary gastric tumor after neoadjuvant trastuzumab-based therapy', Journal of Clinical Oncology, vol. 38, no. 15 suppl, e16529.

APA

Orlova, R., Beliak, N. P., Kutukova, S., Zhukova, N. V., Avramenko, I. V., Popova, N. V., Ivanova, A., Androsova, A., & Zorina, E. (2020). Changing HER2-status of the primary gastric tumor after neoadjuvant trastuzumab-based therapy. Journal of Clinical Oncology, 38(15 suppl), [e16529].

Vancouver

Orlova R, Beliak NP, Kutukova S, Zhukova NV, Avramenko IV, Popova NV et al. Changing HER2-status of the primary gastric tumor after neoadjuvant trastuzumab-based therapy. Journal of Clinical Oncology. 2020;38(15 suppl). e16529.

Author

Orlova, Rashida ; Beliak, Natalia P. ; Kutukova, Svetlana ; Zhukova, Natalia V. ; Avramenko, Inna V. ; Popova, Natalia V. ; Ivanova, Anastasia ; Androsova, Alexandra ; Zorina, Ekaterina . / Changing HER2-status of the primary gastric tumor after neoadjuvant trastuzumab-based therapy. In: Journal of Clinical Oncology. 2020 ; Vol. 38, No. 15 suppl.

BibTeX

@article{1290be8fd06d4c52928b462d4e71c3f4,
title = "Changing HER2-status of the primary gastric tumor after neoadjuvant trastuzumab-based therapy",
abstract = "Background: Aproximetly 16 % of patients with metastatic gastric cancer (GC) have HER2+ tumors. With localized stages, the detection rate of HER2+ is known to be lower. Addition of trastuzumab (T) to chemotherapy (CT) improved survival in metastatic, HER2+ GC. Unlike the metastatic disease, Her-2 did not represent an independent prognostic biomarker for early stages during exploratory analysis of MAGIC trial. The aim of the study was to compare human epidermal growth factor receptor 2 (HER2) expression before and after trastuzumab-based chemotherapy in patients with locally advanced HER2-positive gastric cancer, to evaluate the contribution of trastuzumab to the effectiveness of neoadjuvant treatment in this rare patient population. Methods: We assessed HER2 expression using immunohistochemistry in pre-treatment biopsied specimens and post-treatment resected specimens obtained from 10 patients with locally advanced HER2-positive (3+) gastric cancer receiving trastuzumab-based neoadjuvant chemotherapy: 8 men (80%) and 2 women (20%), from 30 to 80 years old, the median age was 63,5 years. Included 7 patients with resectable adenocarcinoma of the stomach and 3 patients with adenocarcinoma of the esophageal-gastric junction. All patients received neoadjuvant therapy with trastuzumab (100%) + chemotherapy: FLOT (2 patients), FOLFOX (7 patients), XELOX (1 patient). All patients underwent R0 gastrectomy. Tumor regression grading (TRG) after treatment were determined according to Mandard system. Results: Two patients showed a complete pathomorphological response of the tumor (20%,TRG1), therefore, the determination of postoperative HER2 status was not possible. Two patients (20%) maintained the HER2-positive status and six patients (60%) had a change in HER2 expression from positive to negative. Three patients had a (y)pT3 and 5 had a (y)pN+ tumor. Basing on histological changes the tumor regression TRG3 ( < 10% residual tumor cells) was observed in 5 patients (50%). TRG 4-5(preponderance of tumor cells/tumors without changes of regression) observed in 3 patients (30%). The follow-up period is too short for disease-free survival or overall survival to be assessed. Conclusions: HER2 expression can change after trastuzumab-based chemotherapy in patients with locally advanced HER2-positive gastric cancer. Continuous monitoring of HER2 expression after neoadjuvant treatments may be utilized to determine whether the continued use of trastuzumab is advisable.",
author = "Rashida Orlova and Beliak, {Natalia P.} and Svetlana Kutukova and Zhukova, {Natalia V.} and Avramenko, {Inna V.} and Popova, {Natalia V.} and Anastasia Ivanova and Alexandra Androsova and Ekaterina Zorina",
note = "DOI: 10.1200/JCO.2020.38.15_suppl.e16529 Journal of Clinical Oncology 38, no. 15_suppl",
year = "2020",
language = "English",
volume = "38",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "15 suppl",

}

RIS

TY - JOUR

T1 - Changing HER2-status of the primary gastric tumor after neoadjuvant trastuzumab-based therapy

AU - Orlova, Rashida

AU - Beliak, Natalia P.

AU - Kutukova, Svetlana

AU - Zhukova, Natalia V.

AU - Avramenko, Inna V.

AU - Popova, Natalia V.

AU - Ivanova, Anastasia

AU - Androsova, Alexandra

AU - Zorina, Ekaterina

N1 - DOI: 10.1200/JCO.2020.38.15_suppl.e16529 Journal of Clinical Oncology 38, no. 15_suppl

PY - 2020

Y1 - 2020

N2 - Background: Aproximetly 16 % of patients with metastatic gastric cancer (GC) have HER2+ tumors. With localized stages, the detection rate of HER2+ is known to be lower. Addition of trastuzumab (T) to chemotherapy (CT) improved survival in metastatic, HER2+ GC. Unlike the metastatic disease, Her-2 did not represent an independent prognostic biomarker for early stages during exploratory analysis of MAGIC trial. The aim of the study was to compare human epidermal growth factor receptor 2 (HER2) expression before and after trastuzumab-based chemotherapy in patients with locally advanced HER2-positive gastric cancer, to evaluate the contribution of trastuzumab to the effectiveness of neoadjuvant treatment in this rare patient population. Methods: We assessed HER2 expression using immunohistochemistry in pre-treatment biopsied specimens and post-treatment resected specimens obtained from 10 patients with locally advanced HER2-positive (3+) gastric cancer receiving trastuzumab-based neoadjuvant chemotherapy: 8 men (80%) and 2 women (20%), from 30 to 80 years old, the median age was 63,5 years. Included 7 patients with resectable adenocarcinoma of the stomach and 3 patients with adenocarcinoma of the esophageal-gastric junction. All patients received neoadjuvant therapy with trastuzumab (100%) + chemotherapy: FLOT (2 patients), FOLFOX (7 patients), XELOX (1 patient). All patients underwent R0 gastrectomy. Tumor regression grading (TRG) after treatment were determined according to Mandard system. Results: Two patients showed a complete pathomorphological response of the tumor (20%,TRG1), therefore, the determination of postoperative HER2 status was not possible. Two patients (20%) maintained the HER2-positive status and six patients (60%) had a change in HER2 expression from positive to negative. Three patients had a (y)pT3 and 5 had a (y)pN+ tumor. Basing on histological changes the tumor regression TRG3 ( < 10% residual tumor cells) was observed in 5 patients (50%). TRG 4-5(preponderance of tumor cells/tumors without changes of regression) observed in 3 patients (30%). The follow-up period is too short for disease-free survival or overall survival to be assessed. Conclusions: HER2 expression can change after trastuzumab-based chemotherapy in patients with locally advanced HER2-positive gastric cancer. Continuous monitoring of HER2 expression after neoadjuvant treatments may be utilized to determine whether the continued use of trastuzumab is advisable.

AB - Background: Aproximetly 16 % of patients with metastatic gastric cancer (GC) have HER2+ tumors. With localized stages, the detection rate of HER2+ is known to be lower. Addition of trastuzumab (T) to chemotherapy (CT) improved survival in metastatic, HER2+ GC. Unlike the metastatic disease, Her-2 did not represent an independent prognostic biomarker for early stages during exploratory analysis of MAGIC trial. The aim of the study was to compare human epidermal growth factor receptor 2 (HER2) expression before and after trastuzumab-based chemotherapy in patients with locally advanced HER2-positive gastric cancer, to evaluate the contribution of trastuzumab to the effectiveness of neoadjuvant treatment in this rare patient population. Methods: We assessed HER2 expression using immunohistochemistry in pre-treatment biopsied specimens and post-treatment resected specimens obtained from 10 patients with locally advanced HER2-positive (3+) gastric cancer receiving trastuzumab-based neoadjuvant chemotherapy: 8 men (80%) and 2 women (20%), from 30 to 80 years old, the median age was 63,5 years. Included 7 patients with resectable adenocarcinoma of the stomach and 3 patients with adenocarcinoma of the esophageal-gastric junction. All patients received neoadjuvant therapy with trastuzumab (100%) + chemotherapy: FLOT (2 patients), FOLFOX (7 patients), XELOX (1 patient). All patients underwent R0 gastrectomy. Tumor regression grading (TRG) after treatment were determined according to Mandard system. Results: Two patients showed a complete pathomorphological response of the tumor (20%,TRG1), therefore, the determination of postoperative HER2 status was not possible. Two patients (20%) maintained the HER2-positive status and six patients (60%) had a change in HER2 expression from positive to negative. Three patients had a (y)pT3 and 5 had a (y)pN+ tumor. Basing on histological changes the tumor regression TRG3 ( < 10% residual tumor cells) was observed in 5 patients (50%). TRG 4-5(preponderance of tumor cells/tumors without changes of regression) observed in 3 patients (30%). The follow-up period is too short for disease-free survival or overall survival to be assessed. Conclusions: HER2 expression can change after trastuzumab-based chemotherapy in patients with locally advanced HER2-positive gastric cancer. Continuous monitoring of HER2 expression after neoadjuvant treatments may be utilized to determine whether the continued use of trastuzumab is advisable.

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e16529

M3 - Meeting Abstract

VL - 38

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 15 suppl

M1 - e16529

ER -

ID: 89787334